AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Beta Bionics, Inc.
Video analysis: BBNX
All videosNo video analysis for this stock yet. Request one from our team.
News: BBNX
Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The Law Offices of Frank R.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
The lawsuit contends Beta Bionics abandoned a built-in safety net for the iLet dosing algorithm and left more than 18,000 customer complaints uninvestigated, alleged operational failures that reached shareholders only after BBNX had shed 72% of its value.
Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS
SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.
Did You Lose Money Investing in Beta Bionics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against BBNX
San Diego, California--(Newsfile Corp. - September 14, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet").
Beta Bionics Announces FDA Clearance of Mint™, the Company's Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company's addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.
BBNX Shareholders: Beta Bionics Device Safety Issues Trigger Securities Fraud Class Action for Investors – Contact BFA Law if You Lost Money
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 13, 2026NEW YORK, Sept. 13, 2026 /PRNewswire/ -- R
